ESR1 and breast cancer: They found that 6 months of AC-based polyCHT reduces the annual BC death rate by about 38% in women younger than 50 years and by about 20% in older women aged 50–69 years, irrespective of the use of tamoxifen, the ER status, nodal status, or other tumor characteristics.